refractory or relapsed chronic lymphocytic leukemia research hub

A phase II trial of belimumab in combination with rituximab/venetoclax in patients with refractory or relapsed chronic lymphocytic leukemia

This study looks into a new treatment for chronic lymphocytic leukaemia (CLL) that has come back or is hard to treat. It combines a drug called belimumab with existing treatments. Researchers want to see if this combination can get rid of all signs of the cancer in the blood.